[Human parathyroid hormone (1-34) as a new therapeutic agent for osteoporosis].
Human parathyroid hormone (PTH) is used clinically for severe osteoporosis in North America and Europe. The clinical trial is now in progress in Japan. In this review, I introduce the additive effects of PTH with bone resorption inhibitors, the different effects on bone structure and quality between PTH and bone resorption inhibitor, and the bone-increasing effects of PTH involved in IGF/IRS, AP-1 and Wnt pathways. I focus on new topics including the presentations in ASBMR (American Society for Bone and Mineral Research) 2004.